Advertisement

Clinical-features analysis on 926 patients with virological breakthrough in chronic hepatitis B receiving nucleos(t)ide analogues

  • Cheng Huang
    Affiliations
    Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Department of Infectious Diseases and Institute for Virus Hepatitis, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Search for articles by this author
  • Xiang-hui Yang
    Affiliations
    Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Department of Infectious Diseases and Institute for Virus Hepatitis, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    Department of Infectious Diseases of the Ninth People's Hospital of Chongqing Province, Chongqing, China
    Search for articles by this author
  • You-lan Yang
    Affiliations
    Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Department of Infectious Diseases and Institute for Virus Hepatitis, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Search for articles by this author
  • Ai-long Huang
    Affiliations
    Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Department of Infectious Diseases and Institute for Virus Hepatitis, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Search for articles by this author
  • Xiao-Feng Shi
    Correspondence
    Corresponding author at: Key Laboratory of Molecular Biology for Infectious Diseases of Ministry of Education, Department of Infectious Diseases, Institute for Viral Hepatitis, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
    Affiliations
    Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Department of Infectious Diseases and Institute for Virus Hepatitis, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Search for articles by this author
      We read with interest several studies regarding correlated adherence to nucleos(t)ide analogues treatment with the occurrence of resistance or virological breakthrough(VB) [
      • Hilleret M.N.
      • Larrat S.
      • Stanke-Labesque F.
      • Leroy V.
      Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?.
      ,
      • Chotiyaputta W.
      • Peterson C.
      • Ditah F.A.
      • Goodwin D.
      • Lok A.S.
      Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
      ,
      • Chotiyaputta W.
      • Hongthanakorn C.
      • Oberhelman K.
      • Fontana R.J.
      • Licari T.
      • et al.
      Adherence to nucleos(t)ide analogues for chronichepatitis bin clinical practiceandcorrelation with virological breakthroughs.
      ]. These studies showed that poor adherence was associated with an increased risk of VB and resistance, with the incidence rate of resistance related to poor adherence ranging from 5.6 to 50%. These results were quite different. Therefore, we undertook a study to analyze possible trigger factors in the 926 CHB patients receiving NAs and VB.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hilleret M.N.
        • Larrat S.
        • Stanke-Labesque F.
        • Leroy V.
        Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?.
        J Hepatol. 2011; 55: 1468-1469
        • Chotiyaputta W.
        • Peterson C.
        • Ditah F.A.
        • Goodwin D.
        • Lok A.S.
        Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
        J Hepatol. 2011; 54: 12-18
        • Chotiyaputta W.
        • Hongthanakorn C.
        • Oberhelman K.
        • Fontana R.J.
        • Licari T.
        • et al.
        Adherence to nucleos(t)ide analogues for chronichepatitis bin clinical practiceandcorrelation with virological breakthroughs.
        J Viral Hepat. 2012; 19: 205-212
        • Chinese Society of Hepatology and Chinese Society of Infectious Disease
        Chinese medical association. The guideline of prevention and treatment for chronic hepatitis B (2010 version).
        Chin J Hepatol. 2011; 19: 13-24
        • Law S.
        • Manos S.Z.
        • Kermeen I.
        • Holdaway M.
        • Lee S.
        • Zekry A.
        • et al.
        Factors associated with HBV virological breakthrough.
        Antivir Ther. 2017; 22: 53-60
        • Chang T.T.
        • Lai C.L.
        • Chien R.N.
        • Guan R.
        • Lim S.G.
        • Lee C.M.
        • et al.
        Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.
        J Gastroenterol Hepatol. 2004; 19: 1276-1282